Reorganisation of Oncologic Care in Greece: A Proposal

[1] COLLIER R. Drug development cost estimates hard to swallow. Canadian Med Assoc J, 2009, 180:279-28010.1503/cmaj.082040Search in Google Scholar

[2] DIMASI JA, GRABOWSKI HG. Economics of new oncology drug development. J Clin Oncol 2007, 25:209-21610.1200/JCO.2006.09.0803Search in Google Scholar

[3] ΚΑΡΑΜΠΛΗ Ε, ΧΑΤΖΑΚΗ Α, ΠΟΛΥΖΟΣ Ν, ΣΟΥΛΙΩΤΗΣ Κ, ΚΥΡΙΟΠΟΥΛΟΣ Γ. Η επίδραση της τεχνολογικής αλλαγής στη διαχρονική εξέλιξη της δαπάνης υγείας. Αρχ Ελλην Ιατρ 2014, 31:77-84Search in Google Scholar

[4] WHO-International Agency for Research on Cancer. http://eco.iarc.fr/EUCAN/Country.aspx?ISOCountryCd=300Search in Google Scholar

[5] Εθνικό σχέδιο δράσης για τον καρκίνο 2011-2015. Υπουργείο Υγείας και Κοινωνικών Ασφαλίσεων. http://www.anticancer.gov.gr/catalogue/SxedioDrasis_24selido.pdfSearch in Google Scholar

[6] MEROPOL NJ, SCHULMAN KA. Cost of cancer care:issues and implications. J Clin Oncol 2007, 25:180-18610.1200/JCO.2006.09.6081Search in Google Scholar

[7] MARIOTTO AB, YABROFF KR, SHAO Y, FEUER EJ, BROWN ML. Projection of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-12810.1093/jnci/djq495Search in Google Scholar

[8] SULLIVAN R, PEPPERCORN J, SIKORA K, ZALCBERG J, MEROPOL NJ, AMIR E ET AL. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:993-98010.1016/S1470-2045(11)70141-3Search in Google Scholar

[9] AGGRAWAL A. Affordability of cancer care in the UK-Is it time to introduce user changes? J Cancer Policy 2014, 2:31-3910.1016/j.jcpo.2013.11.001Search in Google Scholar

[10] LANG HC. Willingness to pay for lung cancer treatment. Value in Health. Journal of the International Society for Pharmacoeconomics and Outcomes Research 2010, 13:743–74910.1111/j.1524-4733.2010.00743.x20561327Search in Google Scholar

[11] WONG YN, HAMILTON O, EGELSTON B, SALADOR K, MURPHY C, MEROPOL NJ. Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist 2010, 15:566–57610.1634/theoncologist.2009-0307289255620495218Search in Google Scholar

[12] CHEVREUL K, DURAND-ZALESKI I, BAHRAMI SB, HERNANDEZ-QUEVEDO C, MLADOVSKY P. France Health System Review. Health Syst Trans 2010, 12:1-291Search in Google Scholar

[13] TΟΥΝΤΑΣ Γ. O σχεδιασμός των υπηρεσιών υγείας. Αρχ Ελλην Ιατρ 2006, 23:72-83Search in Google Scholar

[14] ΣΟΥΛΙΩΤΗΣ Κ, ΑΘΑΝΑΣΑΚΗΣ Κ, ΓΚΟΛΝΑ Χ, ΠΑΠΑΔΟΠΟΥΛΟΥ Χ, ΚΥΡΙΟΠΟΥΛΟΣ Γ. Περιφερική προσέγγιση των δομών για την φροντίδα των ογκολογικών ασθενών στην Ελλάδα. Αρχ Ελλην Ιατρ 2009, 26:808-817Search in Google Scholar

[15] ΣΟΥΛΙΏΤΗΣ Κ. Μια (επαναλαμβανόμενη) πρόταση για την αναμόρφωση της πολιτικής φαρμάκου στην Ελλάδa. Αρχ Ελλην Ιατρ 2013, 5:519-521Search in Google Scholar